DickSIM
Prima o poi....ci becco!
urgono news per poter tornare a discutere di noicox...
che quella periodica e scontata di oggi sia un antipasto?...
speriamo..
News archive - HUGIN
...sera
![che imbarazzo :-o :-o](/images/smilies/icon_redface.gif)
![Mmmm :mmmm: :mmmm:](/images/smilies/mmmm.gif)
![Lol :lol: :lol:](/images/smilies/lol.gif)
![Lol :lol: :lol:](/images/smilies/lol.gif)
![Prr :prr: :prr:](/images/smilies/prr.gif)
![Prr :prr: :prr:](/images/smilies/prr.gif)
![Prr :prr: :prr:](/images/smilies/prr.gif)
![Censurato :censored: :censored:](/images/smilies/censored.gif)
dici che stanno scaldando i motori?
![arrampicarsi sugli specchi :specchio: :specchio:](/images/smilies/icon_climb2.gif)
![cos'è stato? :-R :-R](/images/smilies/dizzy.gif)
![Help :help: :help:](/images/smilies/help.gif)
urgono news per poter tornare a discutere di noicox...
che quella periodica e scontata di oggi sia un antipasto?...
speriamo..
News archive - HUGIN
urgono news per poter tornare a discutere di noicox...
che quella periodica e scontata di oggi sia un antipasto?...
speriamo..
News archive - HUGIN
Future Recommendations
Part of the uncertainty about NSAID use, including treat-
ment with COX-2 inhibitors, is due to the exclusion of
patients with CV disease from randomized controlled trials,
making it difficult to determine the true risks of NSAIDs for
CV disease. Another difficulty involves the choice of com-
parator ns-NSAIDs in trials of COX-2 inhibitors. Diclofe-
nac, for example, was used for comparison in clinical trials
assessing the efficacy of celecoxib and etoricoxib. However,
diclofenac has been associated with higher CV risk than
other ns-NSAIDs.
The dilution of relative risk associated with many
COX-2 inhibitors over successive studies combined with
the significantly lower rates of their prescription for recur-
rent heart failure suggests that prescribers have heeded
messages that NSAIDs may precipitate heart failure and
other heart conditions in vulnerable individuals and have
applied the same strategy in the use of COX-2 inhibitors.
Future research should include the development of new
medications for pain control. New classes of anti-inflam-
matory and analgesic agents are in development, such as
COX-inhibiting nitric oxide donators56 and selective E pro-
stanoid receptor antagonists.These agents may in-
duce less destabilization of BP control in treated patients
with hypertension, including patients taking renin-angioten-
sin system– blocking drugs. Finally, of special importance
to cardiologists, the possibility of significant adverse inter-
actions between NSAIDs and angiographic contrast agents
should be studied.
un po' difficile avere news da nicox.e' sempre stata molto stitica in questo,ma d'aldronde avendo solo una tecnologia come oggetto e' difficile che esceno news con una certa frequenza.sinceramente ci cono altre societa' che hanno pipeline molto piu' variate e ampie.purtroppo abbiamo cfreduto solo a chiacchiere molto ben costruite.vedi che piu' di quello non sale.le news le devono inventare per poter giocare.escono solo i rumors.resto apatia totale.
Future Recommendations
Part of the uncertainty about NSAID use, including treat-
ment with COX-2 inhibitors, is due to the exclusion of
patients with CV disease from randomized controlled trials,
making it difficult to determine the true risks of NSAIDs for
CV disease. Another difficulty involves the choice of com-
parator ns-NSAIDs in trials of COX-2 inhibitors. Diclofe-
nac, for example, was used for comparison in clinical trials
assessing the efficacy of celecoxib and etoricoxib. However,
diclofenac has been associated with higher CV risk than
other ns-NSAIDs.
The dilution of relative risk associated with many
COX-2 inhibitors over successive studies combined with
the significantly lower rates of their prescription for recur-
rent heart failure suggests that prescribers have heeded
messages that NSAIDs may precipitate heart failure and
other heart conditions in vulnerable individuals and have
applied the same strategy in the use of COX-2 inhibitors.
Future research should include the development of new
medications for pain control. New classes of anti-inflam-
matory and analgesic agents are in development, such as
COX-inhibiting nitric oxide donators56 and selective E pro-
stanoid receptor antagonists.These agents may in-
duce less destabilization of BP control in treated patients
with hypertension, including patients taking renin-angioten-
sin system– blocking drugs. Finally, of special importance
to cardiologists, the possibility of significant adverse inter-
actions between NSAIDs and angiographic contrast agents
should be studied.
Buondi.... Anche a zohar... Italo francese ... Da quel che vedo..![]()